Granite Point Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Granite Point Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,626,667	Closed	-$1.12M	–	228
2020 Q4	$1.12M	Buy	1,626,667 +1,526,667	+1,527%	+$3.25M	0.06%	121
2020 Q3	$225K	Sell	100,000 -800,000	-89%	-$2.28M	0.01%	156
2020 Q2	$3.22M	Buy	900,000 +200,000	+29%	+$722K	0.16%	66
2020 Q1	$2.66M	Sell	700,000 -550,000	-44%	-$1.81M	1.5%	26
2019 Q4	$3.76M	Buy	+1,250,000	New	+$3.25M	0.59%	24

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

WAM

Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Granite Point Capital Management's BMY.RT Position: Q1 2021 in Review

Granite Point Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 1,626,667 shares — an estimated $1.12M sold.

Granite Point Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $3.76M in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Granite Point Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Granite Point Capital Management sold 1,626,667 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $1.12M.
Granite Point Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Granite Point Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $3.76M in Q4 2019.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Granite Point Capital Management's 13F filing for Q1 2021, filed 12 May 2021.